MNKD Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık

03

Fiyat $3.80

Piyasa Değeri (MRQ) $1.18B

P/E (TTM) -29.2

Hisse Başına Kâr (TTM) $-0.13

Gelir (TTM) $394M

ROE (TTM) 71.4%

52 Haftlık Aralık $2–$7

MNKD Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin

04

aralık

çubuklar

Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.

Hisse bölünmeleri 1

Ex-tarihi	Bölünme	Tür
03 Mart 2017	1-for-5	Ters

MannKind Corporation - Common Stock Hakkında Wikipedia'dan şirket genel bakışı

05 · wikidata

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.

MannKind Corporation was named after its founder, Alfred E. Mann.

History

Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

The FDA approved Afrezza on June 27, 2014.

On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.

In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.

Products and product candidates

The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.

Leadership

Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.

In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.

Facilities

MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.

Devamını oku Daha az göster

Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗

Wikidata ↗

sektörHealthcare endüstriBiotechnology çalışanlar591 ülkeUS

10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri

06

Gelir$349M

2016-12-31 → 2025-12-31

Hisse Başına Kâr$0.02

2016-12-31 → 2025-12-31

Serbest Nakit Akışı$14M

2018-12-31 → 2025-12-31

Net kar marjı-11.1%

2017-12-31 → 2025-12-31

Değerleme ve Oranlar 07–12

Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?

Metrik	MNKD	5Y ort.	Akran Ortalaması	Sonuç
P/E (TTM)	-29.25Y ort. ≈45.5	≈45.5	·	·
F/S (TTM)	3.05Y ort. ≈9.1	≈9.1	21.2	Düşük değerli
F/D (MRQ)	-17.55Y ort. ≈-14.7	≈-14.7	·	·
Fiyat / Serbest Nakit Akışı (TTM)	-64.95Y ort. ≈7.7	≈7.7	·	·
Fiyat / Nakit Akışı (TTM)	-146.25Y ort. ≈27.0	≈27.0	·	·
Fiyat / Maddi Defter Değeri (MRQ)	-16.3	·	·	·

Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.

Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC

Metrik	MNKD	5Y ort.	Akran Ortalaması	Sonuç
Faaliyet Kâr Marjı (TTM)	2.3%5Y ort. ≈-17.1%	≈-17.1%	-308.7%	En üst düzey
EBITDA Margin (FAVÖK Marjı)	11.1%5Y ort. ≈-17.1%	≈-17.1%	-308.7%	En üst düzey
Vergi Öncesi Kar Marjı (TTM)	-12.4%5Y ort. ≈-37.8%	≈-37.8%	·	·
Net Kâr Marjı (TTM)	-11.1%5Y ort. ≈-37.9%	≈-37.9%	-214.0%	En üst düzey
ROA (TTM)	-7.6%5Y ort. ≈-12.4%	≈-12.4%	-44.4%	En üst düzey
ROE (TTM)	71.4%5Y ort. ≈10.3%	≈10.3%	-11.7%	Aynı seviyede
ROIC	-316.9%5Y ort. ≈-71.2%	≈-71.2%	-128.0%	Zayıf

Finansal Sağlık Borç, likidite, solventlik — bilanço gücü

Metrik	5 Yıllık trend	MNKD	5Y ort.	Akran Ortalaması	Sonuç
Cari Oran (MRQ)		1.75Y ort. ≈3.3	≈3.3	10.6	Düşük likidite
Cari Oran (MRQ)		1.15Y ort. ≈2.8	≈2.8	5.1	Düşük likidite

Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR

Metrik	MNKD	5Y ort.	Akran Ortalaması	Sonuç
Revenue YoY (Gelir Yıllık Bazda)	22.2%5Y ort. ≈42.6%	≈42.6%	·	·
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)	51.8%5Y ort. ≈50.9%	≈50.9%	·	·
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)	39.9%	·	·	·
EPS YoY (EPS YB)	-80.0%	·	·	·
Net Income YoY (Net Gelir Yıllık Bazda)	-78.8%	·	·	·

Hisse Başı Metrikler Hisse Başı Kâr, hisse başına defter değeri, hisse başına nakit akışı, hisse başına temettü

Metrik	MNKD	5Y ort.	Akran Ortalaması	Sonuç
EPS (Diluted) (Hisse Başına Kar (Seyreltilmiş))	$0.025Y ort. ≈$-0.12	≈$-0.12	·	·
Revenue / Share (Hisse Başına Gelir)	$1.115Y ort. ≈$0.81	≈$0.81	·	·
Cash Flow / Share (Hisse Başına Nakit Akışı)	$0.065Y ort. ≈$0.01	≈$0.01	·	·
Cash / Share (Hisse Başına Nakit)	$0.245Y ort. ≈$0.41	≈$0.41	·	·

Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı

Metrik	MNKD	5Y ort.	Akran Ortalaması	Sonuç
Asset Turnover (Aktif Devir Hızı)	0.65Y ort. ≈0.5	≈0.5	0.3	En üst düzey
Inventory Turnover (Stok Devir Hızı)	0.85Y ort. ≈1.2	≈1.2	·	·
Receivables Turnover (Alacak Devir Hızı)	13.95Y ort. ≈14.7	≈14.7	·	·
Revenue / Employee (Çalışan Başına Gelir)	≈$590.5K	·	·	·

değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme

Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi

14

Ort. Sürpriz -86.3%

Sonraki Rapor Kas 03, 2026

Dönem	Rapor	EPS Gerçek	EPS Tahmin	Sürpriz
30 Haziran 2026	Ağu 12, 2026	$-0.06	$-0.00	—
31 Mart 2026	May 13, 2026	$-0.05	$-0.00	—
31 Aralık 2025		$-0.05	$0.01	-440.1%
30 Eylül 2025		$0.07	$0.02	205.9%
30 Haziran 2025		$0.00	$0.05	-100.0%
31 Mart 2025		$0.04	$0.04	-10.9%

Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı

15

Gelir Tablosu 16

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0	$0
Cost of Revenue	$27M	$17M	$21M	$16M	$17M	$15M	$20M	$19M	$17M	$17M	$65M	·
SG&A Expense	$144M	$94M	$94M	$91M	$32M	$25M	$75M	$80M	$75M	$47M	$41M	$79M
Operating Expenses	$88M	$77M	$63M	$57M	$39M	$25M	$108M	$104M	$120M	$107M	$345M	$180M
Operating Income	$39M	$73M	$9M	$-64M	$-47M	$-48M	$-45M	$-77M	$-108M	$67M	$-345M	$-180M
Interest Expense	·	·	$15M	$15M	$15M	·	·	·	·	·	$24M	$20M
Interest Income	$8M	$13M	$6M	$3M	$112.0K	$167.0K	$997.0K	$501.0K	$293.0K	$85.0K	$18.0K	$9.0K
Other Non-op	$-1M	$32.0K	$122.0K	$-102.0K	$-239.0K	$23.0K	$-926.0K	$-437.0K	$13.0K	$-597.0K	$1M	$2M
Pretax Income	$1M	$31M	$-10M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
Income Tax	$-4M	$3M	$2M	$0	$0	$-218.0K	$0	$240.0K	$51.0K	$0	$0	$0
Net Income	$6M	$28M	$-12M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
EPS (Basic)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	·	$-0.60	$-1.13	$1.37	$-4.54	$-2.57
EPS (Diluted)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	·	$-0.60	$-1.13	$1.36	$-4.54	$-2.57
Shares (Basic)	305,639,000	274,415,000	267,014,000	257,092,000	249,244,000	222,585,000	·	144,136,000	104,245,000	92,053,000	81,233,000	77,045,000
Shares (Diluted)	314,112,000	283,844,000	267,014,000	257,092,000	249,244,000	222,585,000	·	144,136,000	104,245,000	92,085,000	81,233,000	77,045,000
EBITDA	$39M	$73M	$9M	$-64M	$-47M	$-48M	$-45M	$-77M	$-106M	·	$-334M	$-170M

Bilanço 28

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$75M	$46M	$238M	$70M	$124M	$67M	$30M	$71M	$44M	$23M	$59M	$121M
Short-term Investments	$96M	$151M	$57M	$101M	$80M	$0	$20M	·	·	·	·	·
Receivables	$38M	$12M	$15M	$17M	$5M	$4M	$4M	$4M	$3M	$302.0K	$23.0K	$50M
Inventory	$35M	$28M	$29M	$22M	$7M	$5M	$4M	$4M	$3M	$2M	·	$10M
Prepaid Expense	$47M	$31M	$35M	$25M	$3M	$3M	$3M	$3M	$3M	$4M	$4M	$20M
Current Assets	$292M	$268M	$373M	$235M	$219M	$79M	$61M	$82M	$57M	$77M	$77M	$201M
PP&E (Net)	$82M	$85M	$84M	$45M	$37M	$26M	$27M	$26M	$27M	$29M	$49M	$192M
PP&E (Gross)	$196M	$192M	$186M	$144M	$134M	$123M	$122M	$126M	$128M	$129M	$168M	$310M
Accum. Depreciation	$114M	$107M	$102M	$99M	$98M	$97M	$95M	$100M	$101M	$100M	$120M	$118M
Goodwill	$68M	$2M	$2M	$2M	·	·	·	·	·	·	·	·
Intangibles	$5M	$5M	$1M	$1M	·	·	·	·	·	·	·	·
Other Non-current Assets	$20M	$27M	$7M	$10M	$8M	$3M	$6M	$249.0K	$437.0K	$648.0K	$1M	$848.0K
Total Assets	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M
Accounts Payable	$9M	$7M	$10M	$11M	$7M	$6M	$5M	$5M	$7M	$3M	$16M	$7M
Accrued Liabilities	$65M	$40M	$42M	$36M	$27M	$20M	$16M	$15M	$12M	$8M	$8M	$26M
Short-term Debt	·	·	·	·	·	·	$5M	·	·	·	·	·
Current Liabilities	$171M	$82M	$104M	$67M	$48M	$74M	$66M	$75M	$88M	$92M	$268M	$403M
Capital Leases	$11M	$12M	$4M	$5M	$1M	$1M	$3M	·	·	·	·	·
Other Non-current Liabilities	·	·	·	·	$5M	·	·	·	·	·	$15M	$12M
Total Liabilities	$843M	$473M	$721M	$546M	$531M	$289M	$284M	$283M	$299M	$291M	$477M	$468M
Long-term Debt	$355M	$36M	$269M	$273M	$281M	$122M	$119M	$102M	$157M	·	·	·
Total Debt	·	·	·	·	·	·	$5M	·	·	·	·	·
Common Stock	$3M	$3M	$3M	$3M	$3M	$2M	$2M	$2M	$1M	$957.0K	$4M	$4M
Retained Earnings	$-3.20B	$-3.20B	$-3.23B	$-3.22B	$-3.13B	$-3.05B	$-2.99B	$-2.94B	$-2.85B	$-2.74B	$-2.86B	$-2.49B
AOCI	$115.0K	$1M	·	·	·	·	$-19.0K	$-19.0K	$-18.0K	$-24.0K	$-20.0K	$-14.0K
Stockholders' Equity	$-51M	$-79M	$-246M	$-251M	$-209M	$-180M	$-191M	$-175M	$-215M	$-184M	$-350M	$-74M
Liabilities + Equity	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M
Shares Outstanding	307,832,587	302,959,782	270,034,495	263,793,305	251,477,562	242,117,089	211,787,573	187,029,967	119,053,414	95,680,831	85,734,188	406,059,089

Nakit Akışı 18

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
D&A	$12M	$7M	$5M	$3M	$2M	$2M	$972.0K	$3M	$2M	$2M	$11M	$10M
Stock-based Comp	$24M	$21M	$18M	$13M	$12M	$7M	$6M	$7M	$5M	$5M	$9M	$49M
Deferred Tax	$-19M	$4M	$7M	$-10M	$-20M	$-5M	$-5M	$-11M	$-260M	$48M	$-80M	$-66M
Amort. of Intangibles	$4M	·	·	·	·	·	·	·	·	·	·	·
Restructuring	·	·	·	·	·	·	·	·	·	$2M	$6M	$2M
Other Non-cash	·	·	·	·	·	·	·	·	$306M	·	$291M	$144M
Operating Cash Flow	$18M	$43M	$34M	$-81M	$-62M	$-28M	$-88M	$-38M	$-65M	$-78M	$-57M	$4M
CapEx	$5M	$10M	$42M	$8M	$11M	$801.0K	$3M	$354.0K	·	$1M	$10M	$24M
Investing Cash Flow	$-305M	$-97M	$-2M	$5M	$-152M	$15M	$-23M	$-234.0K	$17M	$-1M	·	·
Debt Issued	·	·	·	·	·	$5M	·	·	·	·	·	$20M
Net Debt Issued	·	·	·	·	·	$5M	·	·	·	·	·	·
Stock Issued	·	·	·	·	·	·	·	·	$564.0K	$893.0K	$28M	·
Net Stock Activity	·	·	·	·	·	·	·	·	$564.0K	·	$28M	·
Financing Cash Flow	$315M	$-137M	$137M	$21M	$270M	$50M	$70M	$61M	$74M	$43M	·	·
Net Change in Cash	$29M	$-191M	$169M	$-54M	$57M	$37M	$-41M	$23M	$25M	$-36M	$-62M	$50M
Taxes Paid	$2M	$4M	·	·	·	·	·	·	·	·	·	·
Free Cash Flow	$14M	$33M	$-8M	$-88M	$-73M	$-29M	$-91M	$-38M	·	·	$-68M	$-20M
Levered FCF	·	·	$-26M	$-98M	·	·	·	·	·	·	$-92M	·

Kârlılık 7

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Operating Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-921.1%	·	·	·
Net Margin	1.7%	9.7%	-6.0%	-87.6%	-107.3%	-87.9%	-82.3%	-312.2%	-999.0%	·	·	·
Pretax Margin	0.40%	10.7%	-5.2%	-87.6%	-107.3%	-88.2%	-82.3%	-311.3%	-998.6%	·	·	·
EBITDA Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-905.8%	·	·	·
ROA	0.99%	6.3%	-3.1%	-28.4%	-37.7%	-56.6%	-51.5%	-90.5%	-122.4%	·	-141.5%	-60.8%
ROE	-11.1%	-19.1%	4.8%	35.8%	41.1%	31.2%	27.7%	45.7%	58.9%	·	173.8%	379.7%
ROIC	-316.9%	-83.2%	-4.1%	25.6%	22.5%	26.5%	24.0%	43.9%	50.4%	·	98.4%	·

Likidite ve Solventlik 4

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio	1.7	3.3	3.6	3.5	4.5	1.1	0.9	1.1	0.7	·	0.3	0.5
Quick Ratio	1.2	2.6	3.0	2.8	4.3	1.0	0.8	1.0	0.5	·	0.2	0.4
Debt / Equity	·	·	·	·	·	·	-0.0	·	·	·	·	·
Interest Coverage	·	·	0.6	-6.7	·	·	·	·	·	·	-14.3	-8.8

Verimlilik 3

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.6	0.7	0.5	0.3	0.4	0.6	0.6	0.3	0.1	·	0.0	·
Inventory Turnover	0.8	0.6	0.8	1.1	2.8	3.3	5.2	6.2	6.9	·	·	·
Receivables Turnover	13.9	21.4	12.6	9.3	16.4	16.9	16.7	8.2	7.6	·	0.0	·

Hisse Başına 5

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$-0.17	$-0.26	$-0.91	$-0.95	$-0.83	$-0.75	$-0.90	$-0.94	$-1.80	·	$-0.82	$-0.18
Revenue / Share	$1.11	$1.01	$0.75	$0.39	·	·	·	$0.19	$0.11	·	·	·
Cash Flow / Share	$0.06	$0.15	$0.13	$-0.31	·	·	·	$-0.26	$-0.62	·	·	·
Cash / Share	$0.24	$0.15	$0.88	$0.26	$0.49	$0.28	$0.14	$0.38	$0.37	·	$0.14	$0.30
EPS (TTM)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	$-0.63	$-0.60	$-1.13	$1.36	$-4.54	$-2.57

Büyüme Oranları 5

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	22.2%	43.5%	99.4%	32.2%	15.8%	·	·	·	·	·	·	·
Revenue CAGR 3Y	51.8%	55.8%	45.1%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	39.9%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	-80.0%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	-78.8%	·	·	·	·	·	·	·	·	·	·	·

Değerleme (TTM) 13

Metrik	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0	$0
Net Income TTM	$6M	$28M	$-12M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
Market Cap	$1.75B	$1.95B	$983M	$1.39B	$1.10B	$758M	$273M	$198M	$276M	·	$3.11B	$10.60B
Enterprise Value	·	·	·	·	·	·	$228M	·	·	·	·	·
P/E	283.5	64.3	-91.0	-15.5	-13.7	-12.0	-2.0	-1.8	-2.1	2.4	-1.6	-10.2
P/S	5.0	6.8	4.9	13.9	14.6	11.6	4.3	7.1	23.5	·	·	·
P/B	-34.2	-24.7	-4.0	-5.5	-5.2	-4.2	-1.4	-1.1	-1.3	·	-8.9	-143.7
P / Cash Flow	95.6	45.8	28.8	-17.2	-17.8	-26.9	-3.1	-5.3	-4.3	·	-54.3	2593.8
P / FCF	127.5	59.4	-117.8	-15.7	-15.0	-26.2	-3.0	-5.2	·	·	-46.0	-529.6
EV / EBITDA	·	·	·	·	·	·	-5.1	·	·	·	·	·
EV / FCF	·	·	·	·	·	·	-2.5	·	·	·	·	·
EV / Revenue	·	·	·	·	·	·	3.6	·	·	·	·	·
Earnings Yield	0.35%	1.6%	-1.1%	-6.5%	-7.3%	-8.3%	-48.8%	-56.6%	-48.7%	42.5%	-62.6%	-9.8%

Gelir Tablosu 16

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$109M	$90M	$112M	$82M	$77M	$78M	$77M	$70M	$72M	$66M	$58M	$51M	$49M	$41M	$36M	$33M
Cost of Revenue	$14M	$8M	$14M	$4M	$5M	$4M	$5M	$3M	$6M	$4M	$6M	$4M	$5M	$6M	$4M	$5M
SG&A Expense	$58M	$54M	$58M	$29M	$32M	$25M	$24M	$24M	$24M	$22M	$61M	$11M	$12M	$11M	$64M	$9M
Operating Expenses	$30M	$92M	$-103M	$63M	$21M	$56M	$-86M	$57M	$56M	$50M	$18M	$14M	$14M	$16M	$16M	$17M
Operating Income	$-350.0K	$-2M	$-8M	$19M	$5M	$22M	$26M	$13M	$17M	$17M	$8M	$5M	$2M	$-6M	$-13M	$-10M
Interest Expense	·	·	·	·	·	·	·	·	$6M	$3M	·	$3M	$7M	$3M	·	$3M
Interest Income	$1M	$1M	$2M	$3M	$2M	$2M	$3M	$3M	$3M	$3M	$2M	$2M	$2M	$1M	$957.0K	$663.0K
Other Non-op	$-5M	$-3M	$23M	$-11M	$-4M	$-9M	$24M	$110.0K	$-18M	$-6M	$-164.0K	$318.0K	$-143.0K	$111.0K	$105.0K	$-207.0K
Pretax Income	$-19M	$-16M	$-21M	$8M	$940.0K	$14M	$8M	$13M	$-2M	$11M	$3M	$2M	$-5M	$-10M	$-18M	$-14M
Income Tax	$-106.0K	$253.0K	$-5M	$-204.0K	$272.0K	$459.0K	$1M	$1M	$323.0K	$264.0K	$2M	$0	$0	$0	·	$0
Net Income	$-19M	$-17M	$-16M	$8M	$668.0K	$13M	$7M	$12M	$-2M	$11M	$1M	$2M	$-5M	$-10M	$-18M	$-14M
EPS (Basic)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04	$-0.01	$0.04	$0.01	$0.01	$-0.02	$-0.04	$-0.07	$-0.06
EPS (Diluted)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04	$-0.01	$0.04	$0.01	$0.01	$-0.02	$-0.04	$-0.07	$-0.06
Shares (Basic)	309,191,000	308,267,000	·	306,806,000	304,954,000	303,481,000	·	274,998,000	273,056,000	270,356,000	·	268,732,000	265,626,000	263,969,000	·	259,300,000
Shares (Diluted)	309,191,000	308,267,000	·	311,638,000	311,484,000	320,897,000	·	284,693,000	273,056,000	324,733,000	·	323,770,000	265,626,000	263,969,000	·	259,300,000
EBITDA	·	$-2M	·	$19M	$5M	$22M	·	$13M	$17M	$17M	·	$5M	$2M	$-6M	·	$-10M

Bilanço 25

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$53M	$53M	$75M	$127M	$57M	$47M	$46M	$62M	$97M	$193M	·	$83M	$86M	$86M	·	$54M
Short-term Investments	$58M	$81M	$96M	$133M	$122M	$134M	$151M	$189M	$151M	$107M	·	$58M	$58M	$80M	·	$111M
Receivables	$43M	$28M	$38M	$17M	$27M	$29M	$12M	$18M	$23M	$20M	·	$22M	$28M	$20M	·	$23M
Inventory	$44M	$49M	$35M	$27M	$28M	$29M	$28M	$27M	$25M	$26M	·	$27M	$25M	$22M	·	$18M
Prepaid Expense	$47M	$40M	$47M	$54M	$44M	$34M	$31M	$31M	$30M	$36M	·	$36M	$33M	$15M	·	$12M
Current Assets	$246M	$251M	$292M	$359M	$279M	$274M	$268M	$328M	$326M	$383M	·	$226M	$230M	$223M	·	$218M
PP&E (Net)	$85M	$83M	$82M	$83M	$83M	$84M	$85M	$85M	$85M	$84M	·	$80M	$70M	$55M	·	$41M
PP&E (Gross)	$203M	$198M	$196M	$195M	$194M	$192M	$192M	$192M	$190M	$186M	·	$182M	$170M	$154M	·	$140M
Accum. Depreciation	$118M	$116M	$114M	$113M	$111M	$109M	$107M	$107M	$105M	$103M	·	$101M	$100M	$100M	·	$99M
Goodwill	$68M	$68M	$68M	$2M	$2M	$2M	$2M	$2M	$2M	$2M	·	$2M	$2M	$2M	·	$3M
Intangibles	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$1M	$1M	·	$1M	$1M	$1M	·	$1M
Other Non-current Assets	$17M	$22M	$20M	$19M	$20M	$28M	$27M	$26M	$16M	$7M	·	$8M	$8M	$16M	·	$17M
Total Assets	$732M	$744M	$792M	$495M	$412M	$410M	$394M	$464M	$444M	$481M	·	$320M	$313M	$298M	·	$294M
Accounts Payable	$11M	$16M	$9M	$7M	$10M	$5M	$7M	$6M	$10M	$7M	·	$17M	$17M	$14M	·	$10M
Accrued Liabilities	$61M	$59M	$65M	$31M	$31M	$40M	$40M	$37M	$41M	$42M	·	$32M	$37M	$33M	·	$30M
Current Liabilities	$143M	$135M	$171M	$109M	$112M	$116M	$82M	$72M	$80M	$100M	·	$96M	$97M	$82M	·	$60M
Capital Leases	$10M	$10M	$11M	$10M	$11M	$11M	$12M	$12M	$3M	$4M	·	$4M	$5M	$5M	·	$6M
Total Liabilities	$800M	$804M	$843M	$539M	$467M	$469M	$473M	$674M	$670M	$711M	·	$572M	$574M	$554M	·	$532M
Long-term Debt	$319M	$319M	$355M	$110M	$36M	$36M	$36M	$228M	$228M	$264M	·	$273M	$274M	$274M	·	$273M
Common Stock	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	·	$3M	$3M	$3M	·	$3M
Retained Earnings	$-3.23B	$-3.21B	$-3.20B	$-3.18B	$-3.19B	$-3.19B	$-3.20B	$-3.21B	$-3.22B	$-3.22B	·	$-3.23B	$-3.23B	$-3.23B	·	$-3.20B
AOCI	$-19.0K	$-4.0K	$115.0K	$137.0K	$1M	$1M	$1M	$588.0K	·	·	·	$443.0K	$443.0K	·	·	$-1M
Stockholders' Equity	$-67M	$-59M	$-51M	$-45M	$-55M	$-59M	$-79M	$-210M	$-226M	$-230M	$-246M	$-252M	$-260M	$-255M	$-251M	$-238M
Liabilities + Equity	$732M	$744M	$792M	$495M	$412M	$410M	$394M	$464M	$444M	$481M	·	$320M	$313M	$298M	·	$294M
Shares Outstanding	309,911,682	308,907,331	307,832,587	307,027,189	306,332,133	303,918,969	302,959,782	275,775,038	274,467,247	270,801,781	·	269,543,539	268,235,145	264,278,760	·	263,156,165

Nakit Akışı 11

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$6M	$6M	$6M	$2M	$2M	$2M	$2M	$2M	$2M	$1M	$1M	$1M	$1M	$1M	$1M	$-427.0K
Stock-based Comp	$10M	$6M	$7M	$4M	$8M	$5M	$6M	$5M	$6M	$4M	$4M	$5M	$6M	$4M	$3M	$4M
Amort. of Intangibles	$4M	$4M	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Operating Cash Flow	$-18M	$-5M	$-8M	$24M	$9M	$-6M	$23M	$9M	$4M	$7M	$22M	$9M	$3M	$1M	$-2M	$-28M
CapEx	$5M	$2M	$2M	$1M	$1M	$330.0K	$3M	$1M	$3M	$2M	$6M	$11M	$17M	$8M	$5M	$271.0K
Investing Cash Flow	$18M	$19M	$-292M	$-25M	$6M	$6M	$48M	$-41M	$-55M	$-48M	$-8M	$-12M	$4M	$14M	$15M	$27M
Financing Cash Flow	$559.0K	$-35M	$247M	$72M	$-6M	$1M	$-87M	$-2M	$-45M	$-3M	$142M	$-283.0K	$-6M	$1M	$3M	$20M
Net Change in Cash	$97.0K	$-22M	$-53M	$70M	$10M	$975.0K	$-16M	$-34M	$-96M	$-45M	$155M	$-3M	$315.0K	$16M	$15M	$19M
Taxes Paid	$753.0K	$63.0K	$549.0K	$80.0K	$869.0K	$207.0K	$2M	$236.0K	·	·	·	·	·	·	·	·
Free Cash Flow	·	$-7M	·	·	·	$-7M	·	·	·	$4M	·	·	·	$-7M	·	·
Levered FCF	·	·	·	·	·	·	·	·	·	$2M	·	·	·	$-10M	·	·

Kârlılık 7

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	·	-1.8%	·	23.0%	6.9%	28.4%	·	18.2%	22.9%	25.2%	·	9.9%	3.5%	-14.8%	·	-29.3%
Net Margin	·	-18.4%	·	9.7%	0.87%	16.8%	·	16.5%	-2.8%	16.0%	·	3.4%	-10.8%	-24.1%	·	-44.0%
Pretax Margin	·	-18.1%	·	9.5%	1.2%	17.4%	·	18.4%	-2.3%	16.4%	·	3.4%	-10.8%	-24.1%	·	-44.0%
EBITDA Margin	·	-1.8%	·	23.0%	6.9%	28.4%	·	18.2%	22.9%	25.2%	·	9.9%	3.5%	-14.8%	·	-29.3%
ROA	·	-2.9%	·	1.7%	0.16%	2.9%	·	2.9%	-0.53%	2.7%	·	0.56%	-1.8%	-3.2%	·	-5.4%
ROE	·	28.2%	·	-6.3%	-0.48%	-9.1%	·	-5.0%	0.83%	-4.4%	·	-0.70%	2.1%	4.0%	·	6.8%
ROIC	·	2.9%	·	-43.5%	-6.8%	-36.8%	·	-5.5%	-8.8%	-7.1%	·	-2.0%	-0.66%	2.4%	·	·

Likidite ve Solventlik 3

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	·	1.9	·	3.3	2.5	2.4	·	4.5	4.1	3.8	·	2.3	2.4	2.7	·	3.7
Quick Ratio	·	1.2	·	2.5	1.8	1.8	·	3.7	3.4	3.2	·	1.7	1.8	2.3	·	3.2
Interest Coverage	·	·	·	·	·	·	·	·	2.7	6.5	·	1.8	0.3	-2.5	·	·

Verimlilik 3

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover	·	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.1	·	0.1
Inventory Turnover	·	0.2	·	0.2	0.2	0.1	·	0.1	0.2	0.2	·	0.2	0.2	0.4	·	0.4
Receivables Turnover	·	3.2	·	4.6	3.0	3.2	·	3.5	2.8	3.3	·	2.3	2.3	2.8	·	2.0

Hisse Başına 5

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	·	$-0.19	·	$-0.15	$-0.18	$-0.19	·	$-0.76	$-0.82	$-0.85	·	$-0.93	$-0.97	$-0.97	·	$-0.90
Revenue / Share	·	$0.29	·	$0.26	$0.25	$0.24	·	$0.25	$0.27	$0.20	·	$0.16	$0.18	$0.15	·	$0.13
Cash Flow / Share	·	$-0.02	·	·	·	$-0.02	·	·	·	$0.02	·	·	·	$0.00	·	·
Cash / Share	·	$0.17	·	$0.41	$0.19	$0.16	·	$0.23	$0.35	$0.71	·	$0.31	$0.32	$0.32	·	$0.21
EPS (TTM)	$-0.08	$-0.07	·	$0.10	$0.11	$0.10	·	$0.08	$0.05	$0.04	·	$-0.12	$-0.19	$-0.28	·	$-0.38

Değerleme (TTM) 8

Metrik	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$358M	$361M	·	$314M	$302M	$298M	·	$267M	$248M	$225M	·	$177M	$158M	$128M	·	$76M
Net Income TTM	$-27M	$-24M	·	$29M	$33M	$30M	·	$22M	$12M	$8M	·	$-31M	$-47M	$-71M	·	$-98M
Market Cap	·	$757M	·	$1.65B	$1.15B	$1.53B	·	$1.73B	$1.43B	$1.23B	·	$1.11B	$1.09B	$1.08B	·	$813M
P/E	-53.2	-35.0	·	53.7	34.0	50.3	·	78.6	104.4	113.2	·	-34.4	-21.4	-14.6	·	-8.1
P/S	·	2.1	·	5.3	3.8	5.1	·	6.5	5.8	5.5	·	6.3	6.9	8.4	·	10.7
P/B	·	-12.8	·	-37.0	-20.8	-26.1	·	-8.3	-6.3	-5.3	·	-4.4	-4.2	-4.2	·	-3.4
P / Cash Flow	·	-141.1	·	·	·	-239.7	·	·	·	183.0	·	·	·	937.3	·	·
Earnings Yield	-1.9%	-2.9%	·	1.9%	2.9%	2.0%	·	1.3%	0.96%	0.88%	·	-2.9%	-4.7%	-6.8%	·	-12.3%

En son dönem solda · null değerler · olarak gösterilir

Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl

16

Metrik	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Gelir	$349M	$286M	$199M	$100M	$75M
Faaliyet Kâr Marjı %	11.1%	25.4%	4.4%	-64.3%	-62.3%
Net Gelir	$6M	$28M	$-12M	$-87M	$-81M
Seyreltilmiş Hisse Başı Kâr	$0.02	$0.10	$-0.04	$-0.34	$-0.32

Metrik	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Cari Oran	1.7	3.3	3.6	3.5	4.5
Cari Oran	1.2	2.6	3.0	2.8	4.3

Metrik	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Serbest Nakit Akışı	$14M	$33M	$-8M	$-88M	$-73M

Kurumsal Sahipler (13F) 271 dosya · $883.4M toplam · Tarih itibarıyla 30 Eylül 2026

17

Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.

Sahipler 271

Tutulan Değer $883.4M

Yeni pozisyonlar 51

Çıkan pozisyonlar 39

Kurumsal faaliyet — Q2 2026 ve önceki çeyrek

Yeni pozisyonlar	Çıkan pozisyonlar	Artırıldı	Azaldı	Net hisse senedi değişimi
51 (0 önceki Ç'ye göre)	39 (-8 önceki Ç'ye göre)	98 (+12 önceki Ç'ye göre)	63 (-7 önceki Ç'ye göre)	+1.9M

Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.

Kurum	Değer	Hisse senetleri	% izlenen 13F'nin	Tür
BlackRock, Inc.	$136.887.530	32.133.223	15,50%	Hisse senetleri
VANGUARD GROUP INC	$101.384.549	17.880.873	11,48%	Hisse senetleri
Rubric Capital Management LP	$76.680.000	18.000.000	8,68%	Hisse senetleri
STATE STREET CORP	$68.901.423	16.174.043	7,80%	Hisse senetleri
VANGUARD CAPITAL MANAGEMENT LLC	$56.101.610	13.169.392	6,35%	Hisse senetleri
GEODE CAPITAL MANAGEMENT, LLC	$33.861.886	7.947.203	3,83%	Hisse senetleri
WELLINGTON MANAGEMENT GROUP LLP	$33.418.878	7.844.807	3,78%	Hisse senetleri
Frazier Life Sciences Management, L.P.	$28.116.000	6.600.000	3,18%	Hisse senetleri
Deep Track Capital, LP	$25.560.000	6.000.000	2,89%	Hisse senetleri
180 WEALTH ADVISORS, LLC	$21.126.835	4.959.351	2,39%	Hisse senetleri
FMR LLC	$17.470.455	4.101.046	1,98%	Hisse senetleri
TSP Capital Management Group, LLC	$16.923.596	3.972.675	1,92%	Hisse senetleri
AQR CAPITAL MANAGEMENT LLC	$16.225.589	3.808.824	1,84%	Hisse senetleri
MORGAN STANLEY	$14.802.946	3.474.870	1,68%	Hisse senetleri
BRAIDWELL LP	$14.732.908	3.458.429	1,67%	Hisse senetleri
VANGUARD PORTFOLIO MANAGEMENT LLC	$12.789.240	3.002.169	1,45%	Hisse senetleri
NORTHERN TRUST CORP	$12.299.856	2.887.290	1,39%	Hisse senetleri
UBS Group AG	$12.295.344	2.886.231	1,39%	Hisse senetleri
TWO SIGMA INVESTMENTS, LP	$11.475.213	2.693.712	1,30%	Hisse senetleri
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$11.070.577	2.598.727	1,25%	Hisse senetleri
BANK OF AMERICA CORP /DE/	$10.074.356	2.364.872	1,14%	Hisse senetleri
VANGUARD FIDUCIARY TRUST CO	$9.358.279	2.196.779	1,06%	Hisse senetleri
GOLDMAN SACHS GROUP INC	$9.178.165	2.154.499	1,04%	Hisse senetleri
WELLS FARGO & COMPANY/MN	$6.289.519	1.476.413	0,71%	Hisse senetleri
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$5.030.221	1.180.803	0,57%	Hisse senetleri
DIMENSIONAL FUND ADVISORS LP	$4.661.185	1.094.192	0,53%	Hisse senetleri
Caption Management, LLC	$4.260.000	1.000.000	0,48%	Satım opsiyonu
Bank of New York Mellon Corp	$3.827.454	898.463	0,43%	Hisse senetleri
CITADEL ADVISORS LLC	$3.818.068	896.260	0,43%	Hisse senetleri
J. Goldman & Co LP	$3.478.669	816.589	0,39%	Hisse senetleri
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	$3.019.973	1.232.642	0,34%	Hisse senetleri
SCOPIA CAPITAL MANAGEMENT LP	$2.960.534	694.961	0,34%	Hisse senetleri
Balyasny Asset Management L.P.	$2.914.296	684.107	0,33%	Hisse senetleri
TWO SIGMA ADVISERS, LP	$2.897.166	510.964	0,33%	Hisse senetleri
VICTORY CAPITAL MANAGEMENT INC	$2.771.407	650.565	0,31%	Hisse senetleri
Nuveen, LLC	$2.708.218	635.732	0,31%	Hisse senetleri
Swiss National Bank	$2.502.324	587.400	0,28%	Hisse senetleri
STATE OF WISCONSIN INVESTMENT BOARD	$2.177.052	511.045	0,25%	Hisse senetleri
JACOBS LEVY EQUITY MANAGEMENT, INC	$2.106.540	494.493	0,24%	Hisse senetleri
1492 Capital Management LLC	$2.052.136	481.722	0,23%	Hisse senetleri
Mariner, LLC	$2.020.189	474.236	0,23%	Hisse senetleri
MILLENNIUM MANAGEMENT LLC	$1.836.597	431.126	0,21%	Hisse senetleri
Schonfeld Strategic Advisors LLC	$1.774.216	416.483	0,20%	Hisse senetleri
Squarepoint Ops LLC	$1.759.644	413.062	0,20%	Hisse senetleri
Jefferies Financial Group Inc.	$1.694.202	397.700	0,19%	Hisse senetleri
ExodusPoint Capital Management, LP	$1.666.261	391.141	0,19%	Hisse senetleri
JANE STREET GROUP, LLC	$1.658.418	389.300	0,19%	Alım opsiyonu
PRINCIPAL FINANCIAL GROUP INC	$1.629.561	382.526	0,18%	Hisse senetleri
Man Group plc	$1.624.023	381.226	0,18%	Hisse senetleri
RHUMBLINE ADVISERS	$1.604.647	376.681	0,18%	Hisse senetleri

Tüm 271 kurumsal sahibi göster →

Aktivistler ve %5+ sahipler 2 pozisyon

18

SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.

Başvuru sahibi	Dosyalandı	Hisse	Durum	Amaç	Başvuru
Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 başvurular	10 Temmuz 2012	·	İlk başvuru	Pasif yatırım	SEC
Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi	31 Ocak 2006	·	İlk başvuru	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Şirket yöneticileri 43 içeriden öğrenenler · 27 yöneticiler · 19 yönetim kurulu üyeleri

19

İçeriden Öğrenen	Rol	Son işlem	Sahip olunan hisse senetleri	Alımlar 12ay	Satışlar 12ay	Net 12ay
Michael Castagna	Chief Executive Officer	15 Temmuz 2026 M	2.433.779	1	4	$-990.292
Hakan Edstrom	President & CEO	27 Ağustos 2015 A	1.114.340	0	0	$0
Christopher B Prentiss	Chief Financial Officer	15 Temmuz 2026 F	318.668	0	0	$0
Juergen Martens	Corporate VP and COO	27 Ağustos 2015 A	106.539	0	0	$0
Dominic Marasco	Pres, Endocrine Business Unit	15 Temmuz 2026 F	343.398	0	0	$0
Sanjay R Singh	EVP Technical Operations	15 Temmuz 2026 M	478.966	0	1	$-94.448
Stuart A Tross	Chief People & Workpl Officer	15 Temmuz 2026 M	1.058.142	0	1	$-297.548
David Thomson	EVP Genl Counsel & Secretary	15 Temmuz 2026 M	797.554	0	3	$-930.755
Ajay Ahuja	Chief Medical Officer	23 Mart 2026 A	318.200	0	0	$0
Lauren M Sabella	EVP Operations	15 Temmuz 2025 F	349.841	0	0	$0
Burkhard Blank	EVP Chief Medical Officer	15 Temmuz 2025 F	460.791	0	0	$0
Joseph Kocinsky	Chief Technology Officer	27 Ağustos 2022 F	745.233	0	0	$0
Alejandro Galindo	EVP Endocrine Business Unit	28 Şubat 2022 A	576.690	0	0	$0
Rosabel Realica Alinaya	VP, IR & Treasury	27 Ağustos 2020 A	167.119	0	0	$0
David M Kendall	Chief Medical Officer	31 Temmuz 2020 P	41.059	0	0	$0
Patrick Mccauley	Chief Commercial Officer	25 Şubat 2020 A	83.972	0	0	$0
Courtney Barton	Chief Compl & Privacy Officer	31 Temmuz 2019 P	29.584	0	0	$0
Elizabeth Garrett Ingram	Chief Marketing Officer	14 Mayıs 2019 A	43.012	0	0	$0
Raymond W. Urbanski	Corp VP, CMO	10 Ağustos 2017 S	2.924	0	0	$0
Linda A Adreveno	Sr. VP, HR	18 Şubat 2016 A	92.200	0	0	$0
Alfred E Mann	Executive Chairman	22 Ağustos 2015 F	1.005.990	0	0	$0
Diane Palumbo	Vice President, Human Resource	23 Şubat 2015 F	50.624	0	0	$0
Peter C Richardson	Chief Scientific Officer	03 Mart 2012 F	133.611	0	0	$0
Richard L Anderson	Corporate VP	16 Kasım 2008 F	204.401	0	0	$0
John R. Riesenberger	VP & Chief Commercial Officer	13 Ağustos 2008 A	14.650	0	0	$0
Dan Burns	VP & President, MKBP	08 Aralık 2006 A	14.800	0	0	$0
Wendell W Cheatham	VP, Medical & Reg Affairs	19 Ağustos 2004 A	300	0	0	$0
Steven B. Binder	Yönetim kurulu üyesi	25 Eylül 2026 S	713.258	0	5	$-683.703
Sabrina Kay	Yönetim kurulu üyesi	20 Mayıs 2026 A	265.600	0	0	$0
Jennifer Grancio	Yönetim kurulu üyesi	20 Mayıs 2026 A	244.815	0	0	$0
James Samuel Shannon	Yönetim kurulu üyesi	20 Mayıs 2026 A	64.635	0	0	$0
Michael A Friedman	Yönetim kurulu üyesi	20 Mayıs 2026 A	47.500	0	0	$0
Anthony C Hooper	Yönetim kurulu üyesi	20 Mayıs 2026 A	236.153	0	0	$0
Christine Mundkur	Yönetim kurulu üyesi	20 Mayıs 2026 A	254.493	0	0	$0
Ronald J Consiglio	Yönetim kurulu üyesi	20 Mayıs 2026 A	132.342	0	0	$0
Kent Kresa	Yönetim kurulu üyesi	15 Mayıs 2024 A	274.541	0	0	$0
Henry L Nordhoff	Yönetim kurulu üyesi	14 Mayıs 2019 A	103.426	0	0	$0
David Maccallum	Yönetim kurulu üyesi	16 Mayıs 2018 A	114.790	0	0	$0
Matthew J Pfeffer	Yönetim kurulu üyesi	28 Ağustos 2017 F	81.961	0	0	$0
Abraham E Cohen	Yönetim kurulu üyesi	17 Ağustos 2012 S	56.424	0	0	$0
Heather Hay Murren	Yönetim kurulu üyesi	13 Ağustos 2008 A	10.100	0	0	$0
Kathleen Connell	Yönetim kurulu üyesi	25 Mayıs 2006 A	·	0	0	$0
Llew Keltner	Yönetim kurulu üyesi	25 Mayıs 2006 A	·	0	0	$0

SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış

ETF sahipliği 29 ETF'ler tarafından tutuluyor

20

Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.

Fon	Ağırlık	Birimler	Tarih itibarıyla	Kaynak
JSMD · Janus Detroit Street Trust	0,62%	1.678.187 NS	31 Temmuz 2026	N-PORT
QQQS · Invesco Exchange-Traded Fund Trust …	0,50%	29.891 SH	01 Ekim 2026	Günlük
JSML · Janus Detroit Street Trust	0,49%	450.643 NS	31 Temmuz 2026	N-PORT
FYC · First Trust Exchange-Traded AlphaDE…	0,37%	1.212.660 NS	31 Temmuz 2026	N-PORT
LABU · Direxion Shares ETF Trust	0,23%	289.432 NS	31 Temmuz 2026	N-PORT
FYX · First Trust Exchange-Traded AlphaDE…	0,12%	409.547 NS	31 Temmuz 2026	N-PORT
IBB · iShares Trust	0,08%	2.264.902 SH	11 Eylül 2026	Günlük
IBBQ · Invesco Exchange-Traded Fund Trust …	0,08%	22.737 SH	01 Ekim 2026	Günlük
VTWG · VANGUARD SCOTTSDALE FUNDS	0,08%	330.117 SH	19 Ağustos 2026	Günlük
IWO · iShares Trust	0,08%	2.877.921 SH	11 Eylül 2026	Günlük
FAD · First Trust Exchange-Traded AlphaDE…	0,07%	109.855 NS	31 Temmuz 2026	N-PORT
PWS · Pacer Funds Trust	0,06%	3.954 NS	31 Temmuz 2026	N-PORT
ESML · iShares Trust	0,05%	333.357 SH	11 Eylül 2026	Günlük
VTWO · VANGUARD SCOTTSDALE FUNDS	0,04%	1.771.496 SH	19 Ağustos 2026	Günlük
RSSL · Global X Funds	0,04%	147.059 NS	31 Temmuz 2026	N-PORT
ISCG · iShares Trust	0,04%	96.772 SH	11 Eylül 2026	Günlük
IWM · iShares Trust	0,04%	7.845.946 SH	11 Eylül 2026	Günlük
VHT · VANGUARD WORLD FUND	0,02%	874.372 SH	19 Ağustos 2026	Günlük
FHLC · FIDELITY COVINGTON TRUST	0,02%	139.696 NS	31 Temmuz 2026	N-PORT
VXF · VANGUARD INDEX FUNDS	0,01%	3.543.398 SH	19 Ağustos 2026	Günlük
WSML · iShares Trust	0,01%	16.637 SH	11 Eylül 2026	Günlük
TILT · FlexShares Trust	0,00%	23.700 NS	31 Temmuz 2026	N-PORT
ITOT · iShares Trust	0,00%	465.405 SH	11 Eylül 2026	Günlük
IWV · iShares Trust	0,00%	84.120 SH	10 Eylül 2026	Günlük
DFAC · Dimensional ETF Trust	0,00%	58.407 NS	31 Temmuz 2026	N-PORT
DFAS · Dimensional ETF Trust	0,00%	11.291 NS	31 Temmuz 2026	N-PORT
VTI · VANGUARD INDEX FUNDS	0,00%	9.327.332 SH	19 Ağustos 2026	Günlük
VTHR · VANGUARD SCOTTSDALE FUNDS	0,00%	26.184 SH	19 Ağustos 2026	Günlük
ISCB · iShares Trust	·	13.557 SH	11 Eylül 2026	Günlük

MNKD Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel

21

derecelendirme · 14 analist AL

Medyan hedef $7.50 +97,4%

4 28,6% Güçlü Al

8 57,1% Al

2 14,3% Tut

0 0,0% Sat

0 0,0% Güçlü Sat

12 Aylık Fiyat Hedefi

8 analist · 2026-09-28

Ortalama hedef $7.97 +109,7%

← Tüm hedeflerin altında Mevcut fiyat $3.80

Düşük$4.75 Ortalama$7.97 Yüksek$13.00

Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı

22

Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.

Hisse Sembolü	Piyasa Değeri	P/E	Gelir YoY	Net Kar Marjı	ROE	Brüt Kar Marjı
MNKD	$1.75B	283.5	22.2%	1.7%	-11.1%	·
ORIC	$806M	-5.6	·	·	-36.5%	·
DMRA	·	·	38.3%	-17981.1%	-167.0%	·
REPL	$633M	-2.3	·	·	-146.2%	·
TRAX	·	·	·	·	·	·
BCAX	$953M	-6.7	·	·	-33.0%	·
VOR	$506M	-0.2	·	·	83.4%	·
MGTX	$645M	-5.6	144.6%	-140.3%	8062.2%	·
JANX	$833M	-7.5	-5.5%	-1136.2%	-11.7%	·

Son Haberler Bu şirketten bahseden son manşetler

23

Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” Yahoo Finance · 3 ay, 2 hafta önce MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy Yahoo Finance · 3 ay, 3 hafta önce H.C. Wainwright ve Wells Fargo MannKind (MNKD) Fiyat Hedeflerini Yükseltti Yahoo Finance · 4 ay, 2 hafta önce MannKind Corporation (MNKD) Robinhood'ta Satın Alınacak Popüler Bir Senet mi? Yahoo Finance · 6 ay önce

İşlem Sinyalleri Giriş fiyatı ve risk/ödül oranı ile son alım/satım sinyalleri

25

BOUNCE_UP Zarar durduruldu Ara 23

risk 1 ödül 2,00

giriş $5.89 R:R 2,00

Şu anda açık sinyal yok — hiçbir kart dolu değil ve bu dürüstçe.

Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar

26

Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.

Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.

MNKD MannKind Corporation - Common Stock